DMX AWARDED CONTRACT WITH CARDIOVASCULAR BIOTHERAPEUTICS

Direct Marketing Excellence, Inc., dba DMX Direct, Inc., announces the award of a contract with CardioVascular BioTherapeutics Inc. (CVBT) www.cvbt.com to provide back office services to support investor relations and communications. These services include data processing, design and print production services, collateral fulfillment and distribution.

Amy Montano, Director of Investor Relations stated that, “In DMX Direct we believe we have found a strong partner to help communicate our important messages to our current and potential investors.  Their ability to provide a single source solution for printing and fulfillment of our investor communications as well as their commitment to quality were important reasons we chose DMX.”

Jim Kennel, president of DMX Direct states, “We are very pleased to be working with CardioVascular BioTherapeutics Inc.  We are proud to support CVBT’s dedication to effective treatment of cardiovascular disease.”

About CardioVascular BioTherapeutics Inc.

CardioVascular BioTherapeutics Inc. (CVBT) is a biopharmaceutical company, headquartered in Las Vegas, Nevada, currently focused on developing new drugs for the treatment of cardiovascular disease. Their protein drug candidate, CardioVascu-Grow™, is designed to facilitate growth of new blood vessels in the heart and other tissues and organs with impaired vascular systems.

In two separate clinical trials in Germany in the mid-1990s that Dr. Thomas J. Stegmann conducted, a protein identical in structure to CardioVascu-Grow™ prompted the growth of new blood vessels in the heart and an increased pumping capacity of the heart in the patients treated. CVBT now working to confirm the medical benefits of this protein drug candidate through human clinical trials authorized by the U.S. Food and Drug Administration (FDA). Their clinical trial for no-option heart patients commenced in August 2004, with a network of six major medical centers now included in conducting these trials.

CardioVascular BioTherapeutics, Inc. is committed to conducting additional clinical trials to establish the positive effect of our drug candidate aimed at improving the quality of life for those suffering from heart disease, stroke, diabetic wounds, or peripheral vascular disease, and pledges to continue exploration for additional applications of Cardio Vascu-Grow™.

For more information please visit www.cvbt.com

About DMX Direct, Inc.

Direct Marketing Excellence, Inc., dba DMX Direct, is a Denver, Colorado-based full service direct response marketing services and fulfillment company providing solutions for communication production, distribution and business process outsourcing.  Established in 1991, DMX Direct has built a reputation by servicing both national and regional B2B and B2C clients. DMX Direct mutual fund and shareholder communication services include EDGAR filing, financial printing, statement processing, house-holding, eCommerce, compliance communication direct mail and inquiry / literature inventory and fulfillment.   For more information, please visit www.dmx-direct.com.